false
2026-11-18
0001997296
Medicus Pharma Ltd.
0001997296
2026-11-18
2026-11-18
0001997296
exch:XNCM
mdcx:CommonSharesNoParValueMember
2026-11-18
2026-11-18
0001997296
exch:XNCM
mdcx:WarrantsExercisableForCommonSharesMember
2026-11-18
2026-11-18
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 18, 2026
MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)
|
Ontario
|
001-42408
|
98-1778211
|
| (State or other jurisdiction |
(Commission |
(IRS Employer |
| of incorporation) |
File Number) |
Identification No.) |
300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States
19428
(Address of principal executive offices) (ZIP Code)
Registrant’s telephone number, including area code: (610) 540-7515
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbols |
|
Name of each exchange on which registered |
|
Common shares, no par value
|
|
MDCX
|
|
NASDAQ Capital Market
|
|
Warrants, exercisable for common shares
|
|
MDCXW
|
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).
Emerging growth company ☑
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed in the Current Report on Form 8-K filed by Medicus Pharma Ltd. (the "Company") with the Securities and Exchange Commission (the "SEC") on May 27, 2026, on May 20, 2026, the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that its Market Value of Listed Securities had been below $35 million for the previous 30 consecutive business days and that the Company was therefore not in compliance with Nasdaq Listing Rule 5550(b)(2), and the Company was provided until November 16, 2026 to regain compliance or satisfy an alternative continued listing standard. On November 18, 2026, the Company received a conditional compliance notice (the "Conditional Compliance Notice") from Nasdaq.
The information set forth in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.01.
Item 7.01. Regulation FD Disclosure.
On November 19, 2026, the Company issued a press release regarding the matters described in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.
The information contained in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 8.01. Other Events.
On November 18, 2026, the Company received the Conditional Compliance Notice from the Listing Qualifications Department of Nasdaq notifying the Company that the deficiency relating to the minimum Market Value of Listed Securities requirement set forth in Nasdaq Listing Rule 5550(b)(2) had been lifted because the Company had demonstrated compliance with the alternative minimum shareholders' equity requirement of $2.5 million set forth in Nasdaq Listing Rule 5550(b)(1), giving effect to the completion of the transactions described in the Company's Current Report on Form 8-K filed with the SEC on November 16, 2026.
The Conditional Compliance Notice stated that the Company's compliance is conditioned upon the Company evidencing continued compliance with the minimum shareholders' equity requirement in its next periodic report for the period ending December 31, 2026. If the Company does not evidence compliance with the minimum shareholders' equity requirement in that report, the Company may be subject to delisting from Nasdaq.
There can be no assurance that the Company will be able to maintain compliance with the minimum shareholders' equity requirement, that Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice or that the Company will be able to maintain compliance with Nasdaq's other continued listing requirements in the future.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
Description |
| 99.1 |
Press release issued by Medicus Pharma Ltd. on November 19, 2026. |
| |
|
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements include, but are not limited to, statements concerning the continued listing of the Company's common shares and warrants on Nasdaq, the Company's ability to maintain compliance with the minimum shareholders' equity requirement and Nasdaq's other continued listing requirements, and whether Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Forward-looking statements are typically identified by words such as "plan," "believe," "goal," "target," "aim," "expect," "anticipate," "intend," "outlook," "estimate," "forecast," "project," "continue," "could," "may," "might," "possible," "potential," "predict," "should," "would" and other similar words and expressions, although the absence of these words or expressions does not mean that a statement is not forward-looking.
Forward-looking statements are based on the current expectations and beliefs of the Company's management and are inherently subject to a number of factors, risks, uncertainties and assumptions and their potential effects. There can be no assurance that future developments will be those anticipated. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, risks, uncertainties and assumptions, including the risks and uncertainties described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, as amended, originally filed with the SEC on March 25, 2026, and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the SEC on November 6, 2026, as well as the other risks and uncertainties detailed from time to time in the Company's filings with the SEC. Potential investors, shareholders and other readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company does not assume any obligation to publicly update any forward-looking statement after it was made, whether as a result of new information, future events or otherwise, except as required by law or regulation. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements and the discussion of risk factors contained in the Company's filings with the SEC, which are available at www.sec.gov.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| |
MEDICUS PHARMA LTD. |
| |
|
|
| |
By: |
/s/ Raza Bokhari |
| |
Name: |
Dr. Raza Bokhari |
| |
Title: |
Executive Chairman and Chief Executive Officer |
Dated: November 19, 2026
Exhibit 99.1

Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued Listing
Nasdaq Confirmation follows CEO-Led $4.25 million in Equity Financings and $10.5 million debt exchange to satisfy the alternative minimum shareholders' equity standard.
Philadelphia, PA - November 19, 2026 - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, today announced that it has received written notification on November 18, 2026 (the "Conditional Compliance Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million in shareholders' equity for continued listing on The Nasdaq Capital Market.
Nasdaq based its determination on the transactions described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on November 16, 2026. Additional details may be found in the Company's Current Report on Form 8-K filed with the SEC today.
As previously disclosed, the Company completed approximately $4.25 million in equity financings, comprising a $3.0 million registered direct offering and approximately $1.25 million in private placements led by Company insiders, including a $750,000 investment by Dr. Raza Bokhari through a controlled entity. The Company also exchanged $10.5 million of indebtedness held by Streeterville Capital, LLC for non-convertible preferred shares.
"Nasdaq's confirmation recognizes the progress we have made in strengthening Medicus' balance sheet," stated Dr. Raza Bokhari, Medicus' Executive Chairman and CEO. "My most recent investment alongside other directors and officers reflects our commitment to the Company. We remain focused on disciplined capital allocation and advancing CD228V as the lead program in our precision oncology portfolio."
Under the Conditional Compliance Notice, the Company's compliance is conditioned upon the Company evidencing continued compliance with the minimum shareholders' equity requirement in its next periodic report for the period ending December 31, 2026. If the Company does not evidence compliance in that report, it may be subject to delisting. Nasdaq would provide written notification of any such determination, which the Company could appeal to a Nasdaq Hearings Panel.
The Company remains subject to Nasdaq's other continued listing requirements, and there can be no assurance that it will maintain compliance with the minimum shareholders' equity requirement or other continued listing requirements in the future.
For further information contact:
Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com
Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com
About Medicus Pharma Ltd.
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets. The Company is actively engaged in multiple countries across three continents.
The Company's current therapeutic assets are:
CD228V ADC, an investigational antibody-drug conjugate molecule utilizing Pfizer's established vedotin linker-payload platform, directed against melanotransferrin (CD228), a cell-surface protein expressed across multiple solid tumor types, such as melanoma, squamous non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and esophageal cancer.
SkinJect®, an investigational novel localized immuno-oncology precision product focused on basal cell carcinoma (BCC) lesions in Gorlin Syndrome patients, a rare autosomal dominant disease also called nevoid BCC syndrome.
Teverelix®, an investigational next-generation GnRH antagonist, is being developed as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients, patients with acute urinary retention relapse (AURr) episodes due to enlarged prostate and symptomatic endometriosis.
Medicus' strategy is to advance select programs through Phase 2 proof-of-concept and key clinical and regulatory inflection points that substantially reduce development risk and increase their attractiveness to potential pharmaceutical partners. By generating decision-grade clinical, regulatory and operational datasets, the Company seeks to create opportunities for strategic collaborations, regional licensing transactions and broader commercialization partnerships with established pharmaceutical companies. As data matures across its programs, Medicus intends to continue building differentiated development packages designed to maximize asset value while maintaining capital efficiency and development focus.
Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes "forward-looking statements" or "forward-looking information" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws (collectively, "forward-looking statements"). "Forward-looking statements" are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the continued listing of the Company's securities on Nasdaq, the Company's ability to maintain compliance with the minimum shareholders' equity requirement and Nasdaq's other continued listing requirements, and whether Nasdaq will determine that the Company has satisfied the condition set forth in the Conditional Compliance Notice. Forward-looking statements are often, but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "could," "designed," "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target", "goal", "strive", "prioritize", "pursue", "intended", "potential" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on Form 10-K for the year ended December 31, 2025, as amended, and its quarterly report on Form 10-Q for the quarter ended September 30, 2026, and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
# # #